BrightInsight and Sanofi first launched our partnership in 2022, when the BrightInsight® Platform was selected as the underlying infrastructure to accelerate development of what is now known as the 'MyWay' app, a best-in-class mobile patient app, used by patients in the U.S. and Germany. With 'MyWay' patients can track their flares, injections, medical financials in select countries, and interact directly with their care teams as necessary, eliminating the need for journaling to track their symptoms or additional steps, enabling a seamless and more convenient patient experience.
Following the successful development, launch and scaling of the 'MyWay' app, today I am proud to announce that we have inked an expanded multi-year partnership with Sanofi, that will once again leverage our BrightInsight Platform and Disease Management Solution. Our companies will collaborate to build branded patient apps to drive adoption, adherence, and persistence for Sanofi's future specialty pharma launches.
As their digital partner of choice, we are consistently inspired by Sanofi's commitment to not only develop best-in-class medications for chronic and rare diseases, but also the company's dedication to developing integrated digital services like the 'MyWay' patient app in order to deliver patient support programs, advocacy programs, and other resources and tools to inform and empower patients and their families.
Sanofi will leverage the BrightInsight Platform and Disease Management Solution to quickly build and scale across different brands and markets. The flexibility of the BrightInsight platform allows Sanofi to configure each solution to specific disease populations and market requirements in a fast, patient-centric and compliant manner globally.